Transient myeloproliferative disorder associated with trisomy 21: is a short course of chemotherapy indicated in patients with liver impairment and severe clinical problems?

Med Pediatr Oncol. 1999 Jun;32(6):453-4. doi: 10.1002/(sici)1096-911x(199906)32:6<453::aid-mpo14>3.0.co;2-x.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antibiotics, Antineoplastic / administration & dosage
  • Antimetabolites, Antineoplastic / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cytarabine / administration & dosage
  • Daunorubicin / administration & dosage
  • Down Syndrome / complications*
  • Drug Administration Schedule
  • Dyspnea / etiology
  • Fever / etiology
  • Hepatomegaly / etiology*
  • Hepatomegaly / metabolism
  • Humans
  • Infant, Newborn
  • Male
  • Muscle Weakness / etiology
  • Myeloproliferative Disorders / complications
  • Myeloproliferative Disorders / drug therapy*
  • Myeloproliferative Disorders / genetics
  • Nutrition Disorders / etiology
  • Splenomegaly / etiology

Substances

  • Antibiotics, Antineoplastic
  • Antimetabolites, Antineoplastic
  • Cytarabine
  • Daunorubicin